These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17439935)

  • 1. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension.
    Mok MY; Tsang PL; Lam YM; Lo Y; Wong WS; Lau CS
    Lupus; 2007; 16(4):279-85. PubMed ID: 17439935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
    Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E
    Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
    Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
    Duffels MG; Vis JC; van Loon RL; Nieuwkerk PT; van Dijk AP; Hoendermis ES; de Bruin-Bon RH; Bouma BJ; Bresser P; Berger RM; Mulder BJ
    Am J Cardiol; 2009 May; 103(9):1309-15. PubMed ID: 19406277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
    Monfredi O; Griffiths L; Clarke B; Mahadevan VS
    Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.
    Baptista R; Castro G; da Silva AM; Monteiro P; Providência LA
    Rev Port Cardiol; 2013 Feb; 32(2):123-9. PubMed ID: 23351920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
    Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.
    Keogh AM; McNeil KD; Wlodarczyk J; Gabbay E; Williams TJ
    J Heart Lung Transplant; 2007 Feb; 26(2):181-7. PubMed ID: 17258153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.
    Sitbon O; Gressin V; Speich R; Macdonald PS; Opravil M; Cooper DA; Fourme T; Humbert M; Delfraissy JF; Simonneau G
    Am J Respir Crit Care Med; 2004 Dec; 170(11):1212-7. PubMed ID: 15317666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.
    Safdar Z
    Respir Med; 2009 Nov; 103(11):1688-92. PubMed ID: 19539456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.